» Speaking

WCL's Hot Topics in Drug and Medical Device Regulation

Scott M. Lassman will be participating in a panel discussion on June 19, 2020 on Hot Topics in Drug and Medical Device Regulation, which is part of Washington College of Law's Virtual Summer Series on Health Law and Policy (co-sponsored by the American Health Law Association). He will be presenting on new developments regarding orphan drug exclusivity.

Categories: Speaking

New, Emerging and Continually Interesting Biosimilars Issues

Scott M. Lassman is scheduled to speak about New, Emerging, and Continually Interesting Issues at the Food and Drug Law Institute's Introduction to Biologics and Biosimilars Law and Regulation conference on April 1, 2020.

Categories: Speaking

Exclusivity Webinar

On February 27, 2020, Scott M. Lassman presented a webinar on recent developments affecting exclusivity for drugs and biological products. The webinar was hosted by FDANews.

Categories: Speaking

Biosimilars at the Bar

Scott M. Lassman participated in a panel discussion entitled Biosimilars at the Bar at AAM's GRx+Biosims Conference on November 4, 2019. The panel discussed recent legal developments affecting biosimilars, including interchangeability, labeling carve-outs, enhancements to the Purple Book and regulatory pathways for approval of "biobetters."

Categories: Speaking

New Developments in Biologics and Biosimilars

Scott M. Lassman is scheduled to speak about New, Emerging, and Continually Interesting Issues at the Food and Drug Law Institute's Introduction to Biologics and Biosimilars Law and Regulation on October 2, 2019 in Washington, D.C.

Categories: Speaking

Biosmilars

Scott Lassman spoke on Biosimilars at the Food and Drug Law Institute’s Introduction to Biologics and Biosimilars Conference in Washington, D.C.

Categories: Speaking

The First Amendment: Recent Developments and Impacts on Industry

Scott Lassman spoke on First Amendment issues at the Food and Drug Law Institute's Advertising and Promotion for Medical Products Conference in Washington, D.C.

Categories: Speaking

Hatch-Waxman and BPCIA Overview

Scott Lassman spoke on the Biologics Price Competition and Innovation and Hatch-Waxman Acts at ACI's FDA Boot Camp in Boston.

Categories: Speaking

GRx+Biosims 2018

Scott Lassman spoke on New Biosimilar Developments at the GRx+Biosims 2018 conference in Baltimore.

Categories: Speaking

NYC MedTech Conference

Scott Lassman spoke on biopharma regulatory issues at the NYC MedTech Conference in New York, NY. The conference was a medical technology life science forum hosted by the Consulate General of Hungary in New York.

Categories: Speaking

Scott Lassman

Scott M. Lassman's Profile Image
Scott Lassman has nearly 30 years’ experience in FDA law and policy, both as an in-house attorney and in private practice. He provides strategic advice and advocacy to small, mid-size and large pharmaceutical, biotechnology and medical device companies, as well as the trade associations that represent them and the investors who fund them. His practice covers all aspects of FDA regulatory law, with a special focus on exclusivity, biosimilars, product approval and policy matters...

Read More About Scott

For More Information

  • This field is for validation purposes and should be left unchanged.